Formulation of rifaximin and N-acetylcysteine
JP2025516807A5Pending Publication Date: 2026-05-25CEDARS SINAI MEDICAL CENT
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- CEDARS SINAI MEDICAL CENT
- Filing Date
- 2023-05-19
- Publication Date
- 2026-05-25
AI Technical Summary
Technical Problem
Current treatments for small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) often fail to effectively control bacterial overgrowth and alleviate symptoms due to insufficient penetration of antimicrobial agents through the mucus layer.
Method used
A formulation comprising rifaximin and N-acetylcysteine (NAC) is developed, where rifaximin is encapsulated in a shell with a solid composition, and NAC is coated in multiple mini-tablets, enhancing the delivery and efficacy of the treatment.
Benefits of technology
The formulation effectively reduces bacterial loads in the small intestine, improves stool hardness, and reduces systemic inflammation, providing a more comprehensive treatment for SIBO and IBS.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
Formulations of rifaximin and N-acetylcysteine (NAC) are described herein. Methods of using the formulations for treating various gastrointestinal diseases, including IBS-D and SIBO, are also provided. TIFF2025516807000002.tif131128
Need to check novelty before this filing date? Find Prior Art